TRIM21, a RING‐domain E3 ubiquitin ligase, has been demonstrated to exert diverse biological processes such as tumorigenesis, progression, and therapy resistance.[11, 12, 13, 14] TRIM21 accelerates liver cancer development by inhibiting p62 ubiquitination, thereby reducing the activity of the Keap1‐Nrf2 antioxidant pathway.[11] TRIM21 targets TIF1γ for degradation and promotes the subcellular translocation of active β‐catenin, thereby driving glioblastoma progression.[12] Moreover, TRIM21 also affects the resistance of cancer therapies. This evidence concerns the gene TRIM21 and cancer.